Uri Abadi

Kfar Saba, M, Israel

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 17 publications

Real-World Outcomes of Venetoclax-Based Therapy in Treatment-Naïve and Relapsed/Refractory CLL/SLL: Interim Results From the Prospective REVEAL Study.

Real-World Outcomes of Venetoclax-Based Therapy in Treatment-Naïve and Relapsed/Refractory CLL/SLL: Interim Results From the Prospective REVEAL Study.

Journal: American journal of hematology
Published: April 09, 2026

Single-agent mosunetuzumab in older or unfit patients with previously untreated DLBCL: results of a phase 1/2 trial.

Single-agent mosunetuzumab in older or unfit patients with previously untreated DLBCL: results of a phase 1/2 trial.

Journal: Blood neoplasia
Published: March 20, 2026

Efficacy and safety of Glofitamab in patients with R/R DLBCL in real life setting- a retrospective study.

Efficacy and safety of Glofitamab in patients with R/R DLBCL in real life setting- a retrospective study.

Journal: Annals of hematology
Published: February 25, 2025

Odronextamab monotherapy in R/R DLBCL after progression with CAR T-cell therapy: primary analysis of the ELM-1 study.

Odronextamab monotherapy in R/R DLBCL after progression with CAR T-cell therapy: primary analysis of the ELM-1 study.

Journal: Blood
Published: October 02, 2024

The OHI index predicts early mortality from organ dysfunction and survival benefit from etoposide in patients with lymphoma.

The OHI index predicts early mortality from organ dysfunction and survival benefit from etoposide in patients with lymphoma.

Journal: Blood advances
Published: June 17, 2024

Rituximab versus obinutuzumab-based first-line chemoimmunotherapy for follicular lymphoma-a real-world multicenter retrospective cohort study.

Rituximab versus obinutuzumab-based first-line chemoimmunotherapy for follicular lymphoma-a real-world multicenter retrospective cohort study.

Journal: Annals of hematology
Published: March 03, 2023

Polatuzumab-based regimen or CAR T cell for patients with refractory/relapsed DLBCL-a matched cohort analysis.

Polatuzumab-based regimen or CAR T cell for patients with refractory/relapsed DLBCL-a matched cohort analysis.

Journal: Annals of hematology
Published: October 25, 2021

Nuclear αvβ3 integrin expression, post translational modifications and regulation in hematological malignancies.

Nuclear αvβ3 integrin expression, post translational modifications and regulation in hematological malignancies.

Journal: Hematological oncology
Published: July 12, 2021

αvβ3 Integrin Expression and Mitogenic Effects by Thyroid Hormones in Chronic Lymphocytic Leukemia.

αvβ3 Integrin Expression and Mitogenic Effects by Thyroid Hormones in Chronic Lymphocytic Leukemia.

Journal: Journal of clinical medicine
Published: February 25, 2021

Outcome of relapsed/refractory diffuse large B-cell lymphoma patients treated with polatuzumab vedotin-based therapy: real-life experience.

Outcome of relapsed/refractory diffuse large B-cell lymphoma patients treated with polatuzumab vedotin-based therapy: real-life experience.

Journal: Leukemia & lymphoma
Published: September 28, 2020

Romidepsin treatment for relapsed or refractory peripheral and cutaneous T-cell lymphoma: Real-life data from a national multicenter observational study.

Romidepsin treatment for relapsed or refractory peripheral and cutaneous T-cell lymphoma: Real-life data from a national multicenter observational study.

Journal: Hematological oncology
Published: September 12, 2019

Prevalence and clinical significance of hypercalcemia at diagnosis in diffuse large B-cell lymphoma.

Prevalence and clinical significance of hypercalcemia at diagnosis in diffuse large B-cell lymphoma.

Journal: Leukemia & lymphoma
Published: June 07, 2019
Showing 1-12 of 17

Last Updated: 09/26/2026